Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | CBS | P35520 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212570 | 0.73 | APLNR (0.38) | — | |
| SCHEMBL1876546 | 0.72 | — | — | |
| SCHEMBL14118734 | 0.72 | — | — | |
| SCHEMBL14118417 | 0.69 | — | — | |
| SCHEMBL1694478 | 0.69 | — | — | |
| SCHEMBL1562674 | 0.67 | — | — | |
| SCHEMBL1105653 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL22833116 | 0.66 | — | — | |
| SCHEMBL21351631 | 0.65 | TSHR (0.36) | TSHRCTHCBSTHPOTHRB | |
| Hydrochloric Acid SCHEMBL18107025 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | GLYKOS FINLAND OY (FI) | 2023-08-15 | — | — | US | disclosed |
| US-10973922-B2 | Glycoprotein-toxic payload conjugates | GLYKOS FINLAND OY (FI) | 2021-04-13 | — | — | US | disclosed |
| EP-3613468-A1 | GLYCOPROTEIN-TOXIC PAYLOAD CONJUGATES | Glykos Finland Oy (FI) | 2020-02-26 | — | — | EP | disclosed |
| EP-2991683-B1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | GLYKOS FINLAND OY (FI) | 2019-09-18 | — | — | EP | disclosed |
| US-20180256732-A1 | GLYCOPROTEIN-TOXIC PAYLOAD CONJUGATES | GLYKOS FINLAND OY (FI) | 2018-09-13 | — | — | US | disclosed |
| US-20160106860-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | GLYKOS FINLAND OY (FI) | 2016-04-21 | — | — | US | disclosed |
| EP-2991683-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | Glykos Finland Oy (FI) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015197919-A1 | ANTIBODY DRUG CONJUGATES BINDING TO HIGH-MANNOSE N-GLYCAN | GLYKOS FINLAND OY (FI) | 2015-12-30 | — | — | WO | disclosed |
| WO-2014177771-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | GLYKOS FINLAND OY (FI) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723983-B2 | Conjugates of a glycoprotein or a glycan with a toxic payload | FUT6, CD44, SIGLEC7 | TSHR 202/4885CTH 1773/4885CBS 4486/4885 |
| US-20180256732-A1 | GLYCOPROTEIN-TOXIC PAYLOAD CONJUGATES | SIGLEC7, FUT5, FUT6 | TSHR 1185/4885CTH 3864/4885CBS 4837/4885 |
| US-20160106860-A1 | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC PAYLOAD | FUT5, FUT6, SIGLEC7 | TSHR 914/4885CTH 3736/4885CBS 4795/4885 |
| US-10973922-B2 | Glycoprotein-toxic payload conjugates | SIGLEC7, FUT5, FUT6 | TSHR 1185/4885CTH 3864/4885CBS 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.